Calibration of highly segmented, compact gamma camera for Molecular
  Breast Imaging

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Breast cancers is the second leading cause of cancer mortality in women; early diagnosis increase the probability of a successful therapy; any marginal improvement in this direction helps sparing lives. In this context functional imaging techniques such as Molecular Breast Imaging (MBI) represents an important supplemental screening, especially in the more questionable cases. In order to further extend the MBI performances an innovative asymmetric dual detector device, with mixed optics has been recently proposed and prototyped; the sensors are highly segmented with a correspondingly large number of independent, configurable, electronic readout channels with self-triggering capability. This flexible electronics architecture has different advantages in addition to those related to the adopted asymmetric dual detector geometry: real-time event selection based on the adjustable gain and discriminator threshold at single channel (or group of channels) level; repeatable, quick hardware and software channel response equalization; configurable list mode acquisition for versatile offline image processing. These benefits come at the expenses of more complex calibration methods and optimization procedures, which are detailed in the present paper.

Related collections

Most cited references 7

Record: found
Abstract: found
Article: not found

Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Ahmedin Jemal, Lindsey A Torre, Rebecca Siegel … (2018)

This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions. There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018. In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality. Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality). Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality. The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors. It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries. The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts. CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.

0 comments Cited 26477 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Molecular breast imaging: an emerging modality for breast cancer screening.

Michael O'Connor (2015)

Screening mammography is recognized as an imperfect imaging tool that performs poorly in women with dense breast tissue - a limitation which has driven demand for supplemental screening techniques. One potential supplemental technique is molecular breast imaging (MBI). Significant improvements in gamma camera technology allow MBI to be performed at low radiation doses, comparable with those of tomosynthesis and mammography. A recent screening trial in women with dense breast tissue yielded a cancer detection rate of 3.2 per 1000 for mammography alone and 12.0 per 1000 for the combination of mammography and MBI. MBI also demonstrated a lower recall rate than that of mammography. MBI is a promising supplemental screening technique in women with dense breast tissue.